As deimination is associated with a range of neurodegenerative pathologies including AD, MS and PD [3,19,22,23,26], the prospect of controlled longer-term delivery of PAD inhibitors, including Cl-amidine may offer novel treatment approaches. The gene discussed is PADI4; the disease is myeloid sarcoma.